Skip to content

LBRX LBRX Short-Term Investments

Short-Term Investments at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$912M+0.6%
Alkermes logo
AlkermesALKS
$160.31M-66.9%
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
$254.41M
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$105.02M+315%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$569.25M+22.7%
Septerna, Inc. logo
Septerna, Inc.SEPN
$275.8M+119%

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$874.06M+159%
Enterprise value$556.86M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's short-term investments?
LBRX (LBRX) reported short-term investments of $44.96M in Q1 2026.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.